A Gut Microbe Turns Astaxanthin Into a Cell-Death Shield, Mouse Study Finds

Ferroptosis is a form of cell death driven by iron buildup and runaway lipid oxidation (fat breaking down inside cell membranes), and it has emerged as a major suspect behind intestinal lining damage. A new mouse study, published in the journal Research, traces a surprising path by which a common dietary antioxidant fights that damage: not directly, but through a single species of gut bacterium that converts it into an entirely different, more active molecule. The finding reframes a popular supplement ingredient as something closer to bacterial food than a self-sufficient drug, and it names the specific go-between microbe: Lepagella muris.

Key takeaways

• Astaxanthin (a reddish-orange antioxidant found in salmon, shrimp, and algae) protected mice against intestinal cell death from two different triggers, but only when their gut bacteria were intact.
• A single gut microbe, Lepagella muris, converted astaxanthin into retinoic acid (a vitamin A-derived molecule) in lab culture tests, and retinoic acid then activated a protein called SLC7A11 that shields intestinal cells from ferroptosis.
• Wiping out the mice's gut bacteria with antibiotics erased astaxanthin's protective effect almost entirely.
• Caveat: this is a mouse and cell-culture study only. The bacterium's role is described by the researchers themselves as a candidate contributor, not a proven cause, and there is no human data yet.

Astaxanthin needs gut bacteria to block intestinal ferroptosis

Researchers found that astaxanthin, the carotenoid pigment widely sold as an antioxidant supplement, only protected mouse intestinal tissue from ferroptosis when the animals' gut microbiota was intact. Ferroptosis, defined in a mechanistic review as an iron-dependent cell death process fueled by lipid oxidation, is distinct from more familiar programmed cell death and has been tied to intestinal barrier breakdown. In the new study, mice pretreated with astaxanthin before a dexamethasone (a steroid drug) challenge kept healthier intestinal tissue architecture, lower injury scores, and preserved levels of GPX4 and SLC7A11, the two proteins that form the cell's main defense against ferroptosis. The team also ran a parallel cell-culture experiment using ferrostatin-1, a drug that directly blocks ferroptosis, on dexamethasone-exposed intestinal cells; it produced a similar protective pattern to astaxanthin, reinforcing that ferroptosis specifically, not general inflammation, is the mechanism at work. When the researchers instead gave a separate group of mice a four-drug antibiotic cocktail to wipe out gut bacteria before astaxanthin treatment and a ferroptosis-inducing chemical called Erastin, the protection disappeared almost completely.

Ferroptosis-driven gut injury is a research target across conditions

Ferroptosis has been implicated by prior research in a range of conditions involving intestinal damage, including inflammatory bowel disease (IBD), where oxidative stress and iron dysregulation are already recognized contributors. The mice in this study received a high experimental dose of dexamethasone or Erastin specifically to trigger intestinal ferroptosis, not to model any single human disease. Even so, the injury pattern the researchers documented, loss of the MUC2, ZO-1, and Occludin proteins that normally seal the gut wall, alongside a spike in inflammatory signals (Tnfa, Il6, Il1β, and Il18) and reduced anti-inflammatory Il10, is the type of signature that has drawn ferroptosis researchers to conditions like IBD in the first place. Astaxanthin pretreatment reversed each of these changes in the treated mice.

Metagenomics and a bacterial culture assay pinned down the microbe

To find out which microbe mattered, the team sequenced the mice's gut bacteria (16S rRNA sequencing and shotgun metagenomics) and ran targeted metabolomics on gut and blood samples. Astaxanthin-treated mice showed higher microbial diversity and a metabolic shift toward retinol (vitamin A) metabolism, including elevated retinoic acid. Three candidate bacterial species turned up as enriched in that pathway: Muribaculum gordoncarteri, Muribaculum intestinale, and Lepagella muris. Genome analysis showed only L. muris carried the full enzyme set, including a carotenoid-cleaving enzyme called BCMO1, needed to convert astaxanthin all the way to retinoic acid. Gut microbes are already known to direct how the body handles vitamin A, and this study adds a specific bacterial actor to that picture. The researchers then tested the conversion directly, incubating astaxanthin with each bacterial species in a dish: only L. muris significantly increased retinoic acid production, while M. gordoncarteri showed no effect and M. intestinale mostly accumulated an earlier intermediate instead of finishing the conversion. In a separate cell experiment, applying retinoic acid directly to intestinal epithelial cells reproduced the protective effect, restoring cell viability and SLC7A11/GPX4 activity after an Erastin challenge, and silencing the SLC7A11 gene erased that protection, confirming SLC7A11 as the operating mechanism. A molecular docking simulation estimated a binding score of -6.9 kcal/mol between retinoic acid and SLC7A11, consistent with a direct physical interaction.

What this could mean for someone managing their own gut health

For now, this is not a reason to add an astaxanthin supplement to manage IBD, medication-related gut irritation, or any other condition. The entire experiment was conducted in mice and in isolated cell and bacterial cultures. Whether human gut microbiomes host a Lepagella muris equivalent, or whether human intestinal cells respond the same way to retinoic acid, is unknown. What the study does support is a broader idea already gaining traction in gut research: the reported benefits of a dietary antioxidant or carotenoid may depend on which specific bacteria a person's gut happens to host, not just on how much of the compound is consumed. That is a reason to be skeptical of blanket supplement claims, and if gut symptoms persist, to raise them with a doctor rather than self-treat based on early mechanistic findings like these.

The bacterium's role is a strong correlation, not proven causation

The study's authors are explicit about this limitation themselves. They describe Lepagella muris as an "ASTA-responsive candidate microbial contributor," not a confirmed cause of the retinoic acid increase, and they state that direct evidence, such as colonizing bacteria-free mice with L. muris alone or running a fecal microbiota transplant experiment, would be needed to prove the bacterium actually drives the effect rather than just changing alongside it. The researchers also did not examine other forms of cell death, such as apoptosis, pyroptosis, or necroptosis, that could be contributing to the same injury pattern, and the entire model relies on mouse intestines and a pig-derived intestinal cell line (IPEC-J2), not human tissue.

Next steps involve testing the bacterium directly

The authors call for targeted bacterial colonization experiments and fecal microbiota transplant studies to establish whether Lepagella muris is a true cause of the retinoic acid increase, and ultimately for work in human-relevant models to see if the same diet-microbe-host pathway holds up. No timeline for that follow-up work was given in the paper.

Common Questions

What is astaxanthin? Astaxanthin is a reddish-orange carotenoid pigment naturally produced by algae and found in salmon, shrimp, and other seafood; it is also sold as a standalone antioxidant supplement.

What is ferroptosis? Ferroptosis is a form of cell death triggered by iron and the buildup of oxidized fat inside cell membranes, distinct from more familiar processes like apoptosis, and it has been linked to gut, brain, and heart tissue damage in various studies.

Does this study show astaxanthin supplements help human gut health? No. The findings come entirely from mice and lab-grown cells; the researchers have not tested whether the same bacterium or mechanism exists in humans.

What is SLC7A11? SLC7A11 is a protein on the cell surface that imports the building blocks for glutathione, the cell's main antioxidant molecule, and it is one of the primary defenses cells use against ferroptosis.

References

1. Shuqi Liu, Liang Huang, Sai Xiao, et al. (2026). Astaxanthin Alleviates Intestinal Ferroptosis through Gut Commensal Lepagella muris -Mediated Retinoic Acid Production and SLC7A11 Activation. Research. https://doi.org/10.34133/research.1421
2. Geir Bjørklund, Amin Gasmi, Larysa Lenchyk, et al. (2022). The Role of Astaxanthin as a Nutraceutical in Health and Age-Related Conditions. Molecules. https://doi.org/10.3390/molecules27217167
3. Pengxu Lei, Tao Bai, Yuling Sun (2019). Mechanisms of Ferroptosis and Relations With Regulated Cell Death: A Review. Frontiers in Physiology. https://doi.org/10.3389/fphys.2019.00139
4. Tarun Srinivasan, Chaitanya Dende, Kelly A. Ruhn, et al. (2025). The gut microbiota directs vitamin A flux to regulate intestinal T cell development. https://doi.org/10.1101/2025.09.08.674524